{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:40:36Z","timestamp":1784212836370,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To investigate the effect of simulated weightlessness on the pharmacokinetics of orally administered moxifloxacin and the antacid Maalox or the antidiarrheal Pepto-Bismol using a tail-suspended (TS) rat model of microgravity. Fasted control and TS, jugular-vein-cannulated, male Sprague-Dawley rats received either a single 5\u00a0mg\/kg intravenous dose or a single 10\u00a0mg\/kg oral dose of moxifloxacin alone or with a 0.625\u00a0mL\/kg oral dose of Maalox or a 1.43\u00a0mL\/kg oral dose of Pepto-Bismol. Plasma concentrations of moxifloxacin were measured by HPLC. Pharmacokinetic data were analyzed using WinNonlin. Simulated weightlessness had no effect on moxifloxacin disposition after intravenous administration but significantly decreased the extent of moxifloxacin oral absorption. The coadministration of moxifloxacin with Maalox to either control or TS rats caused significant reductions in the rate and extent of moxifloxacin absorption. In contrast, the coadministration of moxifloxacin with Pepto-Bismol to TS rats had no significant effect on either the rate or the extent of moxifloxacin absorption. These interactions showed dose staggering when oral administrations of Pepto-Bismol and moxifloxacin were separated by 60\u00a0min in control rats but not in TS rats. Dose staggering was more apparent after the coadministration of Maalox and moxifloxacin in TS rats.<\/jats:p>","DOI":"10.1038\/s41598-021-82044-3","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T11:04:39Z","timestamp":1611831879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Oral absorption and drug interaction kinetics of moxifloxacin in an animal model of weightlessness"],"prefix":"10.1038","volume":"11","author":[{"given":"Dong","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,28]]},"reference":[{"key":"82044_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s11095-019-2679-3","volume":"36","author":"S Eyal","year":"2019","unstructured":"Eyal, S. & Derendorf, H. Medications in space: in search of a pharmacologist\u2019s guide to the galaxy. Pharm. Res. 36, 148 (2019).","journal-title":"Pharm. Res."},{"key":"82044_CR2","first-page":"705","volume":"70","author":"L Putcha","year":"1999","unstructured":"Putcha, L., Berens, K. L., Marshburn, T. H., Ortega, H. J. & Billica, R. D. Pharmaceutical use by U.S. astronauts on space shuttle missions. Aviat. Space Environ. Med. 70, 705\u2013708 (1999).","journal-title":"Aviat. Space Environ. Med."},{"key":"82044_CR3","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1096\/fj.14-264838","volume":"29","author":"VE Wotring","year":"2015","unstructured":"Wotring, V. E. Medication use by U.S. crewmembers on the international space station. FASEB J. 29, 4417\u20134423 (2015).","journal-title":"FASEB J."},{"key":"82044_CR4","doi-asserted-by":"publisher","first-page":"e0120126","DOI":"10.1371\/journal.pone.0120126","volume":"10","author":"M Li","year":"2015","unstructured":"Li, M. et al. Broad-spectrum antibiotic or G-CSF as potential countermeasures for impaired control of bacterial infection associated with an SPE exposure during spaceflight. PLoS ONE 10, e0120126 (2015).","journal-title":"PLoS ONE"},{"key":"82044_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/cid\/cis861","volume":"56","author":"LA Mermel","year":"2013","unstructured":"Mermel, L. A. Infection prevention and control during prolonged human space travel. Clin. Infect. Dis. 56, 123\u2013130 (2013).","journal-title":"Clin. Infect. Dis."},{"key":"82044_CR6","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.ejps.2017.05.025","volume":"109S","author":"J Kast","year":"2017","unstructured":"Kast, J., Yu, Y., Seubert, C. N., Wotring, V. E. & Derendorf, H. Drugs in space: pharmacokinetics and pharmacodynamics in astronauts. Eur. J. Pharm. Sci. 109S, S2\u2013S8 (2017).","journal-title":"Eur. J. Pharm. Sci."},{"key":"82044_CR7","first-page":"P161","volume":"6","author":"TR Czarnik","year":"1999","unstructured":"Czarnik, T. R. & Vernikos, J. Physiological changes in spaceflight that may affect drug action. J. Gravit. Physiol. 6, P161\u2013P164 (1999).","journal-title":"J. Gravit. Physiol."},{"issue":"Suppl 1","key":"82044_CR8","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.resp.2009.07.005","volume":"169","author":"AR Hargens","year":"2009","unstructured":"Hargens, A. R. & Richardson, S. Cardiovascular adaptations, fluid shifts, and countermeasures related to space flight. Respir. Physiol. Neurobiol. 169(Suppl 1), S30\u2013S33 (2009).","journal-title":"Respir. Physiol. Neurobiol."},{"key":"82044_CR9","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(80)02208-8","volume":"355","author":"MF Holick","year":"2000","unstructured":"Holick, M. F. Microgravity-induced bone loss\u2013will it limit human space exploration?. Lancet 355, 1569\u20131570 (2000).","journal-title":"Lancet"},{"key":"82044_CR10","first-page":"322","volume":"6","author":"JR Shapiro","year":"2006","unstructured":"Shapiro, J. R. Microgravity and drug effects on bone. J. Musculoskelet. Neuronal Interact. 6, 322\u2013323 (2006).","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"82044_CR11","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1242\/jeb.204.18.3201","volume":"204","author":"RH Fitts","year":"2001","unstructured":"Fitts, R. H., Riley, D. R. & Widrick, J. J. Functional and structural adaptations of skeletal muscle to microgravity. J. Exp. Biol. 204, 3201\u20133208 (2001).","journal-title":"J. Exp. Biol."},{"key":"82044_CR12","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/j.1552-4604.1994.tb02024.x","volume":"34","author":"H Derendorf","year":"1994","unstructured":"Derendorf, H. Pharmacokinetic\/pharmacodynamic consequences of space flight. J. Clin. Pharmacol. 34, 684\u2013691 (1994).","journal-title":"J. Clin. Pharmacol."},{"key":"82044_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1096\/fasebj.4.1.2295381","volume":"4","author":"AH Merrill Jr","year":"1990","unstructured":"Merrill, A. H. Jr. et al. Altered carbohydrate, lipid, and xenobiotic metabolism by liver from rats flown on cosmos 1887. FASEB J. 4, 95\u2013100 (1990).","journal-title":"FASEB J."},{"key":"82044_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1046\/j.1472-8206.2003.00220.x","volume":"18","author":"P Gandia","year":"2004","unstructured":"Gandia, P., Saivin, S., Lavit, M. & Houin, G. Influence of simulated weightlessness on the pharmacokinetics of acetaminophen administered by the oral route: a study in the rat. Fundam. Clin. Pharmacol. 18, 57\u201364 (2004).","journal-title":"Fundam. Clin. Pharmacol."},{"key":"82044_CR15","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/j.1552-4604.1991.tb03658.x","volume":"31","author":"GL Amidon","year":"1991","unstructured":"Amidon, G. L., DeBrincat, G. A. & Najib, N. Effects of gravity on gastric emptying, intestinal transit, and drug absorption. J. Clin. Pharmacol. 31, 968\u2013973 (1991).","journal-title":"J. Clin. Pharmacol."},{"key":"82044_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/j.1472-8206.2005.00374.x","volume":"19","author":"P Gandia","year":"2005","unstructured":"Gandia, P., Saivin, S. & Houin, G. The influence of weightlessness on pharmacokinetics. Fundam. Clin. Pharmacol. 19, 625\u2013636 (2005).","journal-title":"Fundam. Clin. Pharmacol."},{"key":"82044_CR17","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1177\/0091270006291032","volume":"46","author":"P Gandia","year":"2006","unstructured":"Gandia, P., Saivin, S., Le-Traon, A. P., Guell, A. & Houin, G. Influence of simulated weightlessness on the intramuscular and oral pharmacokinetics of promethazine in 12 human volunteers. J. Clin. Pharmacol. 46, 1008\u20131016 (2006).","journal-title":"J. Clin. Pharmacol."},{"issue":"Suppl 1","key":"82044_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2165\/00003088-200140001-00006","volume":"40","author":"H Stass","year":"2001","unstructured":"Stass, H., B\u00f6ttcher, M. F. & Ochmann, K. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400\u00a0mg dose to healthy volunteers. Clin. Pharmacokinet. 40(Suppl 1), 39\u201348 (2001).","journal-title":"Clin. Pharmacokinet."},{"key":"82044_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1255\/ejms.1183","volume":"18","author":"M Cvijovic","year":"2012","unstructured":"Cvijovic, M., Di Marco, V., Traldi, P., Stankov, M. J. & Djurdjevic, P. Mass spectrometic study of speciation in aluminium-fluoroquinolone solutions. Eur. J. Mass Spectrom. (Chichester) 18, 313\u2013322 (2012).","journal-title":"Eur. J. Mass Spectrom. (Chichester)"},{"key":"82044_CR20","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/j.1552-4604.1994.tb02023.x","volume":"34","author":"S Feldman","year":"1994","unstructured":"Feldman, S. & Brunner, L. J. Small animal model of weightlessness for pharmacokinetic evaluation. J. Clin. Pharmacol. 34, 677\u2013683 (1994).","journal-title":"J. Clin. Pharmacol."},{"key":"82044_CR21","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2165\/00003495-199957030-00007","volume":"57","author":"JA Balfour","year":"1999","unstructured":"Balfour, J. A. & Wiseman, L. R. Moxifloxacin. Drugs 57, 363\u2013373 (1999) (discussion 374).","journal-title":"Drugs"},{"key":"82044_CR22","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/clinids\/14.1.272","volume":"14","author":"JM Radandt","year":"1992","unstructured":"Radandt, J. M., Marchbanks, C. R. & Dudley, M. N. Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management. Clin. Infect. Dis. 14, 272\u2013284 (1992).","journal-title":"Clin. Infect. Dis."},{"key":"82044_CR23","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1177\/0091270005276620","volume":"45","author":"EL Schuck","year":"2005","unstructured":"Schuck, E. L., Grant, M. & Derendorf, H. Effect of simulated microgravity on the disposition and tissue penetration of ciprofloxacin in healthy volunteers. J. Clin. Pharmacol. 45, 822\u2013831 (2005).","journal-title":"J. Clin. Pharmacol."},{"issue":"Suppl B","key":"82044_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/jac\/43.suppl_2.69","volume":"43","author":"HM Siefert","year":"1999","unstructured":"Siefert, H. M. et al. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J. Antimicrob. Chemother. 43(Suppl B), 69\u201376 (1999).","journal-title":"J. Antimicrob. Chemother."},{"key":"82044_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/00003495-200262010-00002","volume":"62","author":"GG Zhanel","year":"2002","unstructured":"Zhanel, G. G. et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 62, 13\u201359 (2002).","journal-title":"Drugs"},{"key":"82044_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1365-2125.1992.tb04010.x","volume":"33","author":"NR Campbell","year":"1992","unstructured":"Campbell, N. R., Kara, M., Hasinoff, B. B., Haddara, W. M. & McKay, D. W. Norfloxacin interaction with antacids and minerals. Br. J. Clin. Pharmacol. 33, 115\u2013116 (1992).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"82044_CR27","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1128\/AAC.38.9.2187","volume":"38","author":"L Rambout","year":"1994","unstructured":"Rambout, L., Sahai, J., Gallicano, K., Oliveras, L. & Garber, G. Effect of bismuth subsalicylate on ciprofloxacin bioavailability. Antimicrob. Agents Chemother. 38, 2187\u20132190 (1994).","journal-title":"Antimicrob. Agents Chemother."},{"key":"82044_CR28","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.3748\/wjg.v18.i32.4386","volume":"18","author":"AF Ciccaglione","year":"2012","unstructured":"Ciccaglione, A. F., Cellini, L., Grossi, L. & Marzio, L. Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori. World J. Gastroenterol. 18, 4386\u20134390 (2012).","journal-title":"World J. Gastroenterol."},{"key":"82044_CR29","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1248\/cpb.55.1689","volume":"55","author":"P Djurdjevi\u0107","year":"2007","unstructured":"Djurdjevi\u0107, P., Joksovi\u0107, L., Jeli\u0107, R., Djurdjevi\u0107, A. & Stankov, M. J. Solution equilibria between aluminum(III) ion and some fluoroquinolone family members. Spectroscopic and potentiometric study. Chem. Pharm. Bull. (Tokyo) 55, 1689\u20131699 (2007).","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"issue":"Suppl 1","key":"82044_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2165\/00003088-200140001-00007","volume":"40","author":"H Stass","year":"2001","unstructured":"Stass, H., Sch\u00fchly, U., M\u00f6ller, J. G. & Delesen, H. Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. Clin. Pharmacokinet. 40(Suppl 1), 49\u201355 (2001).","journal-title":"Clin. Pharmacokinet."},{"key":"82044_CR31","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/bcpt.12642","volume":"120","author":"MK Dolberg","year":"2017","unstructured":"Dolberg, M. K., Nielsen, L. P. & Dahl, R. Pharmacokinetic profile of oral magnesium hydroxide. Basic Clin. Pharmacol. Toxicol. 120, 264\u2013269 (2017).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"82044_CR32","doi-asserted-by":"publisher","first-page":"260","DOI":"10.2174\/1573401313666170427162740","volume":"13","author":"JP Schuchardt","year":"2017","unstructured":"Schuchardt, J. P. & Hahn, A. Intestinal absorption and factors influencing bioavailability of magnesium-an update. Curr. Nutr. Food Sci. 13, 260\u2013278 (2017).","journal-title":"Curr. Nutr. Food Sci."},{"key":"82044_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1365-2036.1990.tb00461.x","volume":"4","author":"CU Nwokolo","year":"1990","unstructured":"Nwokolo, C. U., Mistry, P. & Pounder, R. E. The absorption of bismuth and salicylate from oral doses of Pepto-Bismol (bismuth salicylate). Aliment. Pharmacol. Ther. 4, 163\u2013169 (1990).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"82044_CR34","first-page":"899","volume":"71","author":"LJ Brunner","year":"2000","unstructured":"Brunner, L. J., Bai, S. & Abdus-Salaam, H. Effect of simulated weightlessness on phase II drug metabolism in the rat. Aviat. Space Environ. Med. 71, 899\u2013903 (2000).","journal-title":"Aviat. Space Environ. Med."},{"key":"82044_CR35","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/00045391-200109000-00008","volume":"8","author":"VV Ranade","year":"2001","unstructured":"Ranade, V. V. & Somberg, J. C. Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans. Am. J. Ther. 8, 345\u2013357 (2001).","journal-title":"Am. J. Ther."},{"key":"82044_CR36","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/0091270004267193","volume":"44","author":"A Graebe","year":"2004","unstructured":"Graebe, A., Schuck, E. L., Lensing, P., Putcha, L. & Derendorf, H. Physiological, pharmacokinetic, and pharmacodynamic changes in space. J. Clin. Pharmacol. 44, 837\u2013853 (2004).","journal-title":"J. Clin. Pharmacol."},{"key":"82044_CR37","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1177\/0091270003257229","volume":"43","author":"P Gandia","year":"2003","unstructured":"Gandia, P. et al. Influence of simulated weightlessness on the oral pharmacokinetics of acetaminophen as a gastric emptying probe in man: a plasma and a saliva study. J. Clin. Pharmacol. 43, 1235\u20131243 (2003).","journal-title":"J. Clin. Pharmacol."},{"key":"82044_CR38","first-page":"345","volume":"274","author":"LJ Brunner","year":"1995","unstructured":"Brunner, L. J., DiPiro, J. T. & Feldman, S. Antipyrine pharmacokinetics in the tail-suspended rat model. J. Pharmacol. Exp. Ther. 274, 345\u2013352 (1995).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"82044_CR39","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.3748\/wjg.v19.i14.2208","volume":"19","author":"A Roda","year":"2013","unstructured":"Roda, A. et al. Non-invasive panel tests for gastrointestinal motility monitoring within the MARS-500 project. World J. Gastroenterol. 19, 2208\u20132216 (2013).","journal-title":"World J. Gastroenterol."},{"key":"82044_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3357\/ASEM.3153.2012","volume":"83","author":"B Wei","year":"2012","unstructured":"Wei, B., Abobo, C. V., Ma, J. & Liang, D. Gender differences in pharmacokinetics of antipyrine in a simulated weightlessness rat model. Aviat. Space Environ. Med. 83, 8\u201313 (2012).","journal-title":"Aviat. Space Environ. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82044-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82044-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82044-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T02:56:03Z","timestamp":1670036163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82044-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,28]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["82044"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-82044-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,28]]},"assertion":[{"value":"8 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2605"}}